U.S. Markets closed
  • S&P Futures

    4,073.00
    -11.25 (-0.28%)
     
  • Dow Futures

    33,973.00
    -73.00 (-0.21%)
     
  • Nasdaq Futures

    12,177.25
    -45.00 (-0.37%)
     
  • Russell 2000 Futures

    1,913.50
    -6.00 (-0.31%)
     
  • Crude Oil

    79.64
    -0.04 (-0.05%)
     
  • Gold

    1,941.20
    -4.40 (-0.23%)
     
  • Silver

    23.72
    +0.10 (+0.41%)
     
  • EUR/USD

    1.0870
    -0.0005 (-0.0435%)
     
  • 10-Yr Bond

    3.5180
    +0.0250 (+0.72%)
     
  • Vix

    18.51
    -0.22 (-1.17%)
     
  • GBP/USD

    1.2392
    -0.0003 (-0.0211%)
     
  • USD/JPY

    130.0750
    +0.2710 (+0.2088%)
     
  • BTC-USD

    23,661.71
    +507.90 (+2.19%)
     
  • CMC Crypto 200

    537.44
    +20.43 (+3.95%)
     
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • Nikkei 225

    27,473.75
    +91.19 (+0.33%)
     

Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial

  • Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.

  • The study met its primary endpoint with 32.0% of individuals treated with roflumilast cream 0.15% achieving IGA Success – Atopic Dermatitis score of 'clear' or 'almost clear' plus a 2-grade improvement from baseline at Week 4, compared to 15.2% of individuals treated with vehicle.

  • About 43.2% of individuals treated with roflumilast cream 0.15% achieved a 75% reduction in Eczema Area and Severity Index (EASI-75) at Week 4 compared to 22.0% treated with vehicle.

  • Related: Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis.

  • About 33.6% of individuals treated with roflumilast cream achieved a four-point reduction on Worst Itch Numeric Scale at Week 4 (vs. 20.7% for vehicle-treated subjects).

  • Arcutis anticipates topline results from the identically designed pivotal Phase 3 trial INTEGUMENT-2 by the end of 2022.

  • If successful, the company intends to submit a supplemental marketing application in 2023 for roflumilast cream 0.15% for mild to moderate AD in individuals aged six years and older.

  • Price Action: ARQT shares are up 3.55% at $19.38 on the last check Tuesday.

  • Photo Via Company

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.